• (27 May 2021) Sofosbuvir- adding SOF/VEL to the standard of care did not improve the clinical status

  May 31, 2021

  Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial https://doi.org/10.1093/jac/dkab152 IRCT20130812014333N145-This single-centre, randomized, open-labelled, prospective clinical trial was done in patients with moderate to severe COVID-19 admitted to Farabi… Continue reading "(27 May 2021) Sofosbuvir- adding SOF/VEL to the standard of care did not improve the clinical status"

• (21 May 2021) Sofosbuvir- effective in treating patients with moderate COVID-19 infection

  May 28, 2021

  Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1 NCT04530422- Two hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher… Continue reading "(21 May 2021) Sofosbuvir- effective in treating patients with moderate COVID-19 infection"

• (03 Feb 2021) Sofosbuvir-added to the standard of care, SOF accelerated time to the clinical response

  February 5, 2021

  Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial https://doi.org/10.23750/abm.v91i4.10877 IRCT: 20100228003449N29- Clinical response occurred in 91.46% of patients. Although rates of clinical response were comparable between the groups but it occurred faster… Continue reading "(03 Feb 2021) Sofosbuvir-added to the standard of care, SOF accelerated time to the clinical response"